Clotting Factors

Aetna covers specified clotting factor products: Factor VIII agents (e.g., Advate, Adynovate, Eloctate, Kovaltry, Novoeight, Xyntha, etc.) for Hemophilia A (mild disease only after desmopressin failure or for moderate/severe disease), Alphanate/Humate‑P/Koate for von Willebrand disease per subtype or desmopressin nonresponse, and multiple concentrates (Advate, Alphanate, Hemofil M, Humate‑P, Koate, Kogenate FS, Novoeight, Recombinate, Xyntha) for acquired Hemophilia A — Jivi is covered only for patients ≥12 years who have previously received a FVIII product, while FEIBA, Obizur and other agents are restricted to specific listed indications and are considered experimental/investigational for unapproved uses. Precertification is required for clotting factors and many products must be prescribed by or in consultation with a hematologist; specific limits include Jivi’s age/prior‑treatment requirement, FEIBA/Obizur use restrictions (e.g., Obizur not for congenital hemophilia A or VWD and limited by anti‑porcine titer), and exclusion of unlisted indications.